Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells.

ABSTRACT: The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis bacillus Calmette-Guerin (BCG). Despite the fact that this therapy is the most effective treatment for superficial bladder cancer, intravesical administration of BCG is associated with high local morbidity and the potential for systemic infection. Therefore, there is a need for the development of safer, less toxic approaches to fight this disease. Because fibronectin attachment protein (FAP) is a key element in BCG retention and targeting to cells, we hypothesize that this protein can be used as targeting agent to deliver cytotoxic cargo for the treatment of bladder tumors. Here, we evaluated the ability of bladder tumor cells to bind and endocytose FAP via fibronectin

SUBMITTER: Coon BG 

PROVIDER: S-EPMC3276703 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature